Key Findings:
- Histologic and genomic features were analyzed in ER+/HER2- breast cancer tumors stratified by expression of MCM2 and its origin licensing complex (LC).
- High MCM2 expression was associated with features linked to endocrine therapy and CDK4/6 inhibitor resistance.
- High MCM2/LC expression was also associated with the Luminal B breast cancer subtype.